DeepMed Research

Boryung Pharmaceutical Co., Ltd.

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study to Evaluate the Pharmacokinetics and Safety Between Single Administration of "BR6002" and Coadministration of "BR6002A" and "BR6002B" Under Fed Conditions in Healthy Adult Volunteers

Phase 1

Completed

Conditions: Gastric or Duodenal Ulcer

Interventions: Drug: BR6002
Drug: BR6002A
Drug: BR6002B

First Posted Date: 2023-07-25

Last Posted Date: 2023-11-18

Lead Sponsor: Boryung Pharmaceutical Co., Ltd

Target Recruit Count: 40

Registration Number: NCT05959499

Locations: 🇰🇷
Clinical Research Center, H PLUS Yangji Hospital, Seoul, Gwanakgu, Korea, Republic of

A Study to Evaluate Drug-drug Interactions and Safety Between "BR3006-1", "BR3006-2", and "BR3006-3" in Healthy Volunteers

Phase 1

Completed

Conditions: Diabetes Mellitus

Interventions: Drug: BR3006-1
Drug: BR3006-3
Drug: BR3006-2

First Posted Date: 2023-07-19

Last Posted Date: 2023-10-31

Lead Sponsor: Boryung Pharmaceutical Co., Ltd

Target Recruit Count: 37

Registration Number: NCT05951946

Locations: 🇰🇷
CHA Bundang Medical Center(CBMC), Seongnam-si, Gyeonggi-do, Korea, Republic of

A Study to Evaluate the Efficacy and Safety of BR1017A and BR1017B Combination Therapy in Essential Hypertension Patients With Primary Hypercholesterolemia

Phase 3

Completed

Conditions: Essential Hypertension
Primary Hypercholesterolemia

Interventions: Drug: Fimasartan
Drug: Ezetimibe/Atorvastatin
Drug: Ezetimibe/Atorvastatin Placebo
Drug: Fimasartan Placebo

First Posted Date: 2023-07-05

Last Posted Date: 2024-10-18

Lead Sponsor: Boryung Pharmaceutical Co., Ltd

Target Recruit Count: 148

Registration Number: NCT05930028

Locations: 🇰🇷
Severance Hospital, Seoul, Korea, Republic of

A Study to Evaluate the Efficacy and Safety of BR1015 Combination Therapy

Phase 3

Completed

Conditions: Essential Hypertension

Interventions: Drug: Fimasartan + Indapamide
Drug: Fimasartan + Indapamide placebo

First Posted Date: 2023-05-26

Last Posted Date: 2024-12-20

Lead Sponsor: Boryung Pharmaceutical Co., Ltd

Target Recruit Count: 248

Registration Number: NCT05878561

Locations: 🇰🇷
The Catholic University of Korea, Bucheon St.Mary's Hospital, Bucheon-si, Kyunggi-do, Korea, Republic of

A Clinical Trial Study to Evaluate the Pharmacokinetic Interaction and Safety Between BR1019-1 and BR1019-2 in Healthy Adult Subjects

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2
Hypertension

Interventions: Drug: BR1019-1
Drug: BR1019-2
Drug: BR1019-1 + BR1019-2

First Posted Date: 2023-05-25

Last Posted Date: 2023-09-28

Lead Sponsor: Boryung Pharmaceutical Co., Ltd

Target Recruit Count: 36

Registration Number: NCT05875259

Locations: 🇰🇷
Inha University Hospital, Incheon, Korea, Republic of

An Observational Study to Analyze the Prescription Pattern of Sugammadex and Its Effectiveness and Safety

Recruiting

Conditions: Postoperative Complications
Neuromuscular Blockade
Anesthesia

First Posted Date: 2023-03-29

Last Posted Date: 2025-04-03

Lead Sponsor: Boryung Pharmaceutical Co., Ltd

Target Recruit Count: 7000

Registration Number: NCT05788718

Locations: 🇰🇷
Korea University Anam Hospital, Seoul, Seongbuk-gu, Korea, Republic of

An OS to Evaluate the Safety & Efficacy of Fixed Dose Combination Therapy With Atorvastatin and Ezetimibe

Recruiting

Conditions: Primary Hypercholesterolemia

First Posted Date: 2022-09-29

Last Posted Date: 2024-08-23

Lead Sponsor: Boryung Pharmaceutical Co., Ltd

Target Recruit Count: 2700

Registration Number: NCT05559606

Locations: 🇰🇷
Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of

A Study to Evaluate the Pharmacokinetic Interaction and Safety Between BR1018-1 and BR1018-2 in Healthy Adult Subjects

Phase 1

Completed

Conditions: Hypertension
Hyperlipidemia (E.G., Hypercholesterolemia)

Interventions: Drug: BR1018-1
Drug: BR1018-2

First Posted Date: 2022-07-15

Last Posted Date: 2023-05-24

Lead Sponsor: Boryung Pharmaceutical Co., Ltd

Target Recruit Count: 36

Registration Number: NCT05460364

Locations: 🇰🇷
Inha University Hospital, Incheon, Korea, Republic of

A Study to Evaluate the Pharmacokinetics After Administration of BR3003 and Co-administration of BR3003B and BR3003C.

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: BR3003(T)
Drug: BR3003B(R1)
Drug: BR3003C(R2)

First Posted Date: 2022-06-09

Last Posted Date: 2022-07-27

Lead Sponsor: Boryung Pharmaceutical Co., Ltd

Target Recruit Count: 48

Registration Number: NCT05411965

Locations: 🇰🇷
Clinical Research Center, H PLUS Yangji Hospital, Seoul, Gwanakgu, Korea, Republic of

An OS to Evaluate Effectiveness and Safety of Fixed-dose Combinations of FMS/AML or FMS/AML/HCTZ

Recruiting

Conditions: Hypertension,Essential

First Posted Date: 2022-06-09

Last Posted Date: 2024-05-22

Lead Sponsor: Boryung Pharmaceutical Co., Ltd

Target Recruit Count: 20000

Registration Number: NCT05413057

Locations: 🇰🇷
Seoul National University Bundang Hospital, Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy